We can’t show the full text here under this license.
GLP-1 receptor drugs and heart health in people with type 2 diabetes and kidney disease: A review and combined analysis
Updated
Abstract
A total of 7130 patients were analyzed to evaluate cardiovascular outcomes of glucagon-like peptide-1 receptor agonists in those with type 2 diabetes and chronic kidney disease.
- No significant reduction was observed in composite cardiovascular outcomes among patients with type 2 diabetes and chronic kidney disease receiving glucagon-like peptide-1 receptor agonists.
- The odds ratio for the composite cardiovascular endpoint was 0.80, with a 95% confidence interval of 0.59-1.07, indicating no strong evidence for benefit.
- Individual components of cardiovascular outcomes did not show evidence of a reduction associated with glucagon-like peptide-1 receptor agonists.
- The findings suggest that while some glucagon-like peptide-1 receptor agonists may provide cardiovascular benefits, this is not consistent across all medications in this class.
- Patients with chronic kidney disease and type 2 diabetes are advised to use glucagon-like peptide-1 receptor agonists with proven cardiovascular benefits to reduce risk.
Simplified
Key numbers
0.80
Odds Ratio for Composite Cardiovascular Outcome
Odds ratio comparing GLP1-RA to placebo in patients with CKD
7130
Number of Patients Analyzed
Total number of patients with CKD included in the meta-analysis